Michael G. Palfreyman, phd, dsc
Michael is the Co-Founder and Chief R&D Officer at Alnivo Therapeutics. As an independent consultant and President of Palfreyman BioPharm Advisors, Inc., he brings more than four decades of experience in pre-clinical research and early clinical development of multiple CNS, infectious diseases, ophthalmic, respiratory, gastrointestinal, cancer, cardiovascular, and metabolic compounds in both biotechnology and pharmaceutical industry settings.
He has been Senior R&D Advisor to Cybin, Inc. with two ongoing clinical programs where I led the discovery and early pre-clinical development of two novel psychedelic compounds for treating Major Depressive Disorder and Generalized Anxiety Disorder. He was a co-inventor on two issued US patents related to these compounds; he is also an Advisor to the NIH-HEAL Program developing new treatments for pain and an R&D Advisor to MAK Scientific supporting an RO1 grant from the NIAAA for Alcohol Use Disorder. This program is in advanced IND-enabling studies under his leadership. He previously held several executive positions at Psychiatric Genomics, Scriptgen (Anadys) Pharmaceuticals, as well as Marion Merrell Dow Research Institute (Sanofi), and Beecham Pharmaceuticals (Glaxo Smith Kline). In addition to overseeing research programs in Psychiatric, Neurological, Cardiovascular, Cancer, Infectious, Ophthalmic, Metabolic, and Respiratory Disorders, his own research included the discovery and development of several psychotherapeutic compounds for the treatment of psychosis, depression, anxiety, stroke, epilepsy, emesis, Parkinson’s, Alzheimer’s and Huntington’s diseases. Most recently, I have overseen and directed the development of multiple novel compounds, including psychedelics. Many of these compounds have entered clinical development and reached the marketplace.
He is the co-inventor on 56 issued US and European patents, 12 pending patents, and over 150 scientific articles and book chapters. This broad experience in research leadership positions in both the pharmaceutical and biotechnology industries will help Alnivo Therapeutics develop the HSP70 program for therapeutic applications in dermatological wound healing studies, guide and partner clinical programs with CROs, raise capital, develop its patent portfolio, develop partnerships and commercialize the HSP70 assets.